Last reviewed · How we verify
NCT04150666
The Water Intake Trail and Primary Aldosteronism Postoperation(WIT-PAP)
NA trial testing Hydration in Hyperaldosteronism. Withdrawn.
1 May 2020
Quick facts
| Lead sponsor | Qifu Li |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 1 December 2019 |
| Primary completion | 1 May 2020 |
| Estimated completion | 1 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Hydration — full drug profile →
Conditions studied
- Hyperaldosteronism — all drugs for Hyperaldosteronism →
- Renal Insufficiency — all drugs for Renal Insufficiency →
Sponsor
Qifu Li — full company profile →
Who can join
Adults 18 to 75, any sex, with Hyperaldosteronism or Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate whether increasing water intake has renal protective effect on PA patients after surgical treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04150666
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hydration
Trials testing the same drug.
- NCT07291375 — Role of Amlodipine in Reduction of CIN · EARLY_PHASE1 · not yet recruiting
- NCT06714929 — Advancing Water Security: A Community Participatory School-Based Hydration Intervention · NA · recruiting
Other recruiting trials for Hyperaldosteronism
Currently open trials in the same condition.
- NCT07252284 — CHina Adrenal Venous saMPling InvestigatiON · recruiting
- NCT06246357 — Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisoli · Phase 2 · recruiting
- NCT05925569 — Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension · NA · active not recruiting
- NCT07328230 — Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism · NA · recruiting
- NCT04328181 — Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomo · NA · recruiting
Other Qifu Li trials
Trials by the same sponsor.
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06955286 — Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Witho · recruiting
- NCT06635993 — Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Auton · recruiting
- NCT06833437 — 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent · NA · recruiting
- NCT06457074 — Finerenone for Patients With Primary Aldosteronism (FAIRY) · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04150666 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qifu Li
- Last refreshed: 15 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04150666.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing